Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

Farragher, TM, Lunt, M, Plant, D, Bunn, D, Barton, A and Symmons, DPM (2010) Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care & Research, 62 (5). pp. 664-675. ISSN 2151-4658

Full text not available from this repository.

Abstract

Objective To compare the clinical utility of anti–cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) testing in predicting both functional outcome and response to treatment in early inflammatory polyarthritis (IP) patients. Methods A total of 916 IP subjects from a primary care incidence registry (1990–1994) had anti-CCP antibody and RF status determined at baseline. Mean change in Health Assessment Questionnaire (HAQ) score between baseline and 5 years was compared by antibody status. The effect of treatment with disease-modifying antirheumatic drugs and/or steroids over 5 years, early (

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: Rhiannon Harvey
Date Deposited: 07 Mar 2012 11:57
Last Modified: 28 Aug 2018 14:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/38005
DOI: 10.1002/acr.20207

Actions (login required)

View Item